EU Plant 2 GMP Push Drives Akums’ FY28 CDMO Outlook

Akums Drugs & Pharmaceuticals Limited — Q4 FY26 & FY26 Earnings Call (held May 18, 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly emphasizes “strong note” and “business momentum” despite H1 headwinds.
• They highlight multiple positive catalysts: EU GMP accreditation (Plant 2), Zambia project on track, trade generics turning EBITDA positive, and margin expansion in domestic branded formulations.
• However, they still acknowledge ongoing pain in API (cephalosporins pricing pressure) and provide cautious language on some forward outcomes (e.g., “hopeful”, “wait for at least a couple of quarters”).

2. Key Themes from Management Commentary

• CDMO momentum + structural demand shift
• “CDMO once again delivered a healthy top line growth led by double-digit volume expansion”
• Claims structural strength from “growing customer preference for compliant manufacturers”.
• EU expansion progressing from accreditation to filings
• EU GMP accreditation for Plant 2 received in January; “commenced dossier filing and country-specific registrations”.
• Plan: “commence commercial supplies from Plant 2 in FY28”.
• Zambia JV execution
• “project remains on track” with expected ~$25m supplies from Indian facilities by end of Q2 FY27, plus local facility planning/erection.
• Domestic branded formulations: margin-led improvement
• “margins expanded meaningfully” validating “efficiency-focused strategy”.
• Expectation: “grow at above IPM rates” in FY27.
• International branded formulations: muted year, expected recovery
• “tough year with muted growth” due to “market-specific disruption”; expect return to growth based on “structural attractiveness”.
• API: cephalosporin pricing pressure continues; losses expected to reduce
• “pricing pressure in the cephalosporin persisted… resulting in continued losses”
• Mitigation plan: “cost optimization, portfolio rationalization, yield improvements, and gradual shift towards higher margin non-cephalosporin products”.
• European audit of API facility expected next quarter to unlock regulated opportunities.
• Trade generics: turnaround
• “turned a corner in this quarter” and expects stabilized but smaller profit footprint.
• Operational/digital transformation
• SAP S/4HANA “progressing as per plan”; Darwinbox delivering “tangible employee experience benefit”.
• Capex + ramp-up of newer facilities
• Capex “broadly in line with trend run rate”; newer facilities (injectable plant, Penem facility, Baddi plant) ramping with audits/approvals advanced.
• Cash generation
• Operating cash flow and free cash flow materially improved (attributed to European contract assignment/advance mechanics).

3. Q&A Analysis

Theme A: Regulated market readiness (EU CDMO) — capability gaps & investments

• Core question(s):
• What internal capabilities are least scalable for EU/regulatory markets (regulatory throughput, quality systems, tech transfer, leadership bandwidth, manufacturing facility)?
• What concrete investments are being made to become “regulated-market-ready”?
• Management response:
• Points to existing regulated experience: serving MNCs in India for 15+ years; first European GMP approval in 2022.
• Mentions Plant 3 also received ANVISA approval this year.
• States key dosage forms are already EU/regulated approved; plans for additional plants’ EU GMP approvals in “next 18 months”.
• Assessment (evasive/strong/partial):
• Partial: did not clearly quantify the “least scalable” bottleneck; answered at a high level (“capabilities across R&D, quality, production, regulatory”).
• Strong: provided specific milestones (Plant 2 accreditation, dossier filings, Plant 3 ANVISA).

Theme B: CDMO margin mechanics vs API input price movements

• Core question(s):
• With API price volatility, what is the net effect on CDMO gross margins?
• Does CDMO markup behave as % of input cost (and how does that affect absolute profits)?
• Management response:
• CDMO is “passthrough business model”; input cost uncertainty is passed through via contracts; margins depend on conversion/margins.
• Explicitly confirmed: CDMO model uses percent margins on input cost.
• Assessment:
• Unusually clear on the model: “This model is a percent margins on the input cost.”
• Confirms that if input costs fall, absolute gross profit can fall even if % margin holds.

Theme C: CDMO volume growth drivers & sustainability

• Core question(s):
• Why volume variance has been >25% in last two quarters?
• Is it sustainable, and what drives it (new customers/geographies vs existing customers)?
• Management response:
• Volume growth primarily from existing customers only; increased demand for existing brands.
• Claims similar double-digit growth visibility into Q1; suggests sustained growth.
• Assessment:
• Partial: “still to be thought through” on exact driver; no quantified wallet-share analysis.
• Sustainability is asserted but not evidenced with customer-level metrics.

Theme D: Trade generics and API outlook (FY27 and beyond)

• Core question(s):
• How do trade generics and API businesses look for FY27 and beyond?
• When does API losses reduce / when can it turn monthly EBITDA positive?
• Tax rate expectations.
• Management response:
• Trade generics: EBITDA positive now; expects similar revenue and EBITDA, “not meaningfully contribute” to group.
• API: “a year of miss”; expects “much better” than FY26; losses reduced but full-year may still be negative.
• Monthly EBITDA positive: “goal and aspiration”; “wait for at least a couple of quarters”.
• Tax: guided to ~29% overall; current ~32% due to loss-making entities.
• Assessment:
• Evasive on timing: no firm date for API breakeven; uses “hopeful/aspiration”.
• Credible on trade generics: clearly framed as capital-preservation, smaller footprint.

Theme E: Domestic branded formulations growth & margin strategy

• Core question(s):
• Why international branded revenue declined but margins improved?
• How will domestic business deliver at par with IPM and achieve double-digit growth?
• Management response:
• International branded: margin expansion from marketing focus (B2B2C) and FX/ForEx gain.
• Domestic: cautious pricing (“hardly took a price hike”), focus on volume; expects growth “in line with IPM” and “double-digit top line growth” in domestic formulation business in future.
• Assessment:
• Strong: explains margin uplift drivers (marketing mix + FX).
• Cautious: domestic growth depends on volume and future pricing dynamics (“yet to be seen” elsewhere in transcript).

Theme F: Capex, cash usage, and dividend policy

• Core question(s):
• Capex for FY26 and FY27.
• Plan for cash usage given only 18% dividend payout.
• Management response:
• Capex: FY26 INR222 crores, FY27 target INR300 crores.
• Cash usage: growth-focused—organic capex (oral solids ramp-up) and potential inorganic acquisitions; “actively evaluating” niche acquisitions.
• Assessment:
• Clear on capex; non-committal on top-line guidance (explicit refusal to give FY27 revenue target).

Theme G: Zambia and European contract economics/timelines

• Core question(s):
• Zambia contract structure: annual amounts, ramp-up, multi-year nature, facility investment.
• EU contract: annual run-rate and margin sensitivity to inflation; how much revenue in FY28; FX impact.
• Management response:
• Zambia: two years $25m each FY27 & FY28 from Indian facilities; supplies from Zambia facility expected later (FY29/FY30).
• Investment: $45m total, 51% borne by Akums.
• EU: fixed price contract till 2032; expects margins “similar or high teens”; comfort zone at current API prices.
• FY28 mix: export CDMO share ~15%+ of CDMO revenues (based on their “Excel” framing).
• Assessment:
• Strong: provides contract duration and MAT run-rate.
• Potentially optimistic: “comfort zone” language on inflation risk without showing sensitivity.

4. Guidance / Outlook

Explicit guidance (quantitative)

• Capex
• FY26 capex: INR222 crores
• FY27 capex target: INR300 crores
• Zambia
• Expected commercial supplies from Indian facilities: ~$25m by end of Q2 FY27
• Contract supplies: $25m each for FY27 and FY28
• Total investment: $45m, Akums share 51%
• Zambia facility revenue start: FY29/FY30 (management mentions “calendar year ’29” / “FY29 is somewhere… FY29 or FY30”)
• EU CDMO
• Plant 2 commercial supplies: FY28
• EU contract MAT run-rate: EUR35m (stated as “for the next six years till 2032”)
• Expected margin: “similar or high teens”
• Trade generics
• Expected to remain at “similar levels of revenue with similar levels of EBITDA” (no numeric revenue given)
• Tax
• Target overall tax rate: ~29% (current ~32% due to losses)

Implicit signals (qualitative)

• CDMO
• Expects double-digit volume growth in Q1/Q2; H2 pricing still uncertain.
• Margin profile expected to be “similar margin profile” to current levels.
• API
• Losses expected to reduce “sharply” but full-year losses may remain negative.
• Monthly EBITDA positive: “goal and aspiration” but timing deferred (“couple of quarters”).
• Domestic branded formulations
• Expects above IPM growth and “double-digit top line growth” in domestic formulation business.
• International branded formulations
• Expects return to growth; margins likely supported by marketing mix and FX.

5. Standout Statements (direct / highly revealing)

• CDMO model clarity (pricing mechanics):
• “This model is a percent margins on the input cost.”
• EU ramp-up milestone:
• “EU GMP accreditation of our Plant 2 received in January… commenced dossier filing… in line with… commence commercial supplies from Plant 2 in FY28.”
• Zambia execution timing:
• “commercial supplies of approximately $25 million… expected to commence by the end of Q2 FY27”
• Trade generics turnaround framing:
• “turned a corner… expect a stabilized though much smaller profit-oriented footprint”
• API uncertainty acknowledged:
• “we are hopeful…” and “we’ll have to wait for at least a couple of quarters” for monthly EBITDA positivity.
• Cash flow improvement attribution:
• “Operating cash flow… majorly attributable to the European contract that was assigned to the company.”
• Dividend/cash usage stance:
• “primary usage of the cash still remains… assessing organic or inorganic opportunities for growth.”

6. Red Flags / Positive Signals

Red flags
– API breakeven timing remains vague: repeated deferrals (“hopeful”, “couple of quarters”, “full year still negative”).
– Volume growth driver not fully explained: management admits “still to be thought through” why volume variance is high.
– Margin comfort zone relies on current API prices for EU fixed-price contract: “fairly confident this remains our comfort zone” (no sensitivity).
– No FY27 revenue guidance: explicit refusal to provide future numbers.

Positive signals
– Regulated market progress is tangible: Plant 2 EU GMP accreditation, dossier filings, and clear FY28 commercialization plan.
– Trade generics profitability improvement is quantified (EBITDA turned positive in Q4).
– Strong liquidity and cash generation: cash and cash equivalents INR1,682 crores; free cash flow INR958 crores.
– Operational execution: SAP S/4HANA and Darwinbox “progressing as per plan” with tangible benefits.

7. Historical Comparison & Consistency Analysis (vs prior 3 calls)

a. Change in Tone Over Time

• Q1 FY26 (Aug 2025): optimistic about global CDMO journey; emphasized approvals and ramp-ups; API losses reducing.
• Q2 FY26 (Nov 2025): more cautious—API price downtrend and margin dip; “underperforming” quarter; still confident long-term.
• Q3 FY26 (Feb 2026): improved tone—CDMO strong, international branded recovery, EU project on track; API losses contained sequentially.
• Current Q4 FY26 (May 2026): most optimistic—management calls out “strong note” and multiple turnarounds (trade generics EBITDA positive, domestic margins expanded, EU accreditation achieved).

Shift classification: More Optimistic
– More confidence in execution milestones (EU accreditation achieved; dossier filings started).
– More explicit “turning” narratives (trade generics, API losses expected to curtail).
– Still cautious on API timing, but overall confidence is higher.

b. Tracking Past Commitments vs Outcomes

1) EU Plant 2 commercialization timing
– Past statement (Q3 FY26, Feb 2026): “on track to start supplies in FY ’28” after EU GMP accreditation.
– Current (Q4 FY26, May 2026): EU GMP accreditation “received in January”; “commenced dossier filing”; still “commence commercial supplies… in FY28”.
– Status: ✅ Delivered on milestone (accreditation achieved; filings started; timeline maintained).

2) Zambia supplies from Indian facilities
– Past statement (Q3 FY26, Feb 2026): “commercial supplies from the Indian plants expected in H1 of FY ’27” (~$25m).
– Current: “expected to commence by the end of Q2 FY27” (~$25m).
– Status: ⏳ Slightly delayed (H1 vs end of Q2 is close, but not exactly “H1 early”; still within H1).

3) Trade generics turnaround
– Past statement (Q2 FY26, Nov 2025): consolidation to reduce losses; EBITDA still negative.
– Current: “turned a corner in this quarter” and trade generics EBITDA positive in Q4.
– Status: ✅ Delivered (turnaround achieved).

4) API losses reduction / breakeven
– Past statement (Q4 FY25, May 2025): losses to be curtailed; “losses… half by end of this year” and FY27 breakeven aspiration.
– Current: “losses… expected to curtail” but “full year would still remain negative”; monthly EBITDA positive requires “a couple of quarters”.
– Status: ❌ Not fully delivered (breakeven not achieved; timing remains deferred).

c. Narrative Shifts

• API narrative shifts from “turnaround in progress” to “year of miss” (more candid) but still without a firm breakeven date.
• Trade generics shifts from “consolidation / provisions” to “stabilized smaller footprint” (clear strategic exit framing).
• Domestic branded shifts from “steady trajectory” to “margins expanded meaningfully validating efficiency strategy” (margin-led story now stronger).
• EU shifts from “progressing as per plans” to “accreditation achieved + dossier filings started” (execution credibility improved).

d. Consistency & Credibility Signals

• High credibility on milestones (EU accreditation, dossier filings, trade generics EBITDA positive, capex targets).
• Medium credibility on forward profitability:
• API breakeven timing keeps slipping/softening.
• Management uses “hopeful/aspiration” language more than in earlier calls.
• Overall credibility: Medium (execution is improving, but profitability timelines—especially API—remain uncertain).

e. Evolution of Key Themes

• Demand/volumes: improving and increasingly attributed to “existing customer demand” and compliance preference.
• Margins: CDMO margins stabilizing; domestic margins improving; API remains the drag.
• Expansion: EU and Zambia are now in “execution mode” (accreditation/filings/supplies).
• Regulatory: Schedule M and regulated market readiness discussed, but Schedule M Q&A included a refusal to speculate on government rollout impact.

f. Additional Insights (cross-period intelligence)

• Cash flow strength is partly contract/accounting-driven (European contract assignment/advance mechanics). This boosts liquidity but does not automatically translate into sustainable operating profitability—especially given API losses persist.
• Management is increasingly explicit that CDMO margins are structurally linked to % input cost, which implies that gross margin upside may be limited unless product mix improves—yet they still project margin improvement in future contracts (EU) without showing sensitivity.
• Defensiveness in Q&A is mild but present around API timing and Schedule M rollout (“no visibility”).